Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal | Synapse
March 5, 2026Open Access
Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal
Key Points
To evaluate the cost effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) in older adults in Portugal.
Economic evaluation of vaccine costs and health outcomes
Assessment of cost-effectiveness per age group
Comparison of RZV with standard prevention strategies
RZV is cost-effective for preventing HZ in adults aged 65 years and older.
Cost effectiveness increases for individuals aged 65-69 years due to reduced complication rates.
Abstract
RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.